Abraxis news from FiercePharma
NewsCosts put cancer docs in financial bind
Pricey cancer meds aren't just putting the squeeze on patients and insurers. They're putting oncologists in a financial quandary as well. We got an inkling of this recently when the American Society... Read more...
| Press ReleasesAbraxis BioScience, Inc. and ProMetic Life Sciences Inc. (PFSCF.PK) Enter License Agreements for Up to $295M US For Four BiopharAbraxis BioScience, Inc. and ProMetic Life Sciences Inc. (PFSCF.PK) Enter License Agreements for Up to $295M US For Four Biopharmaceuticals Abraxis Makes Initial $7 M US Equity Investment in Read more >> |
Get more Abraxis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
